NCT04253561 2026-03-16
IPATHER
SOLTI Breast Cancer Research Group
Phase 1 Completed
Clinical Trials
16 trialsNCT03959891 2025-09-29
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT04486352 2025-09-04
EndoMAP
Alliance Foundation Trials, LLC.
Phase 1/2 Recruiting
NCT03673787 2025-05-14
IceCAP
Institute of Cancer Research, United Kingdom
Phase 1/2 Active not recruiting
NCT05332561 2025-03-20
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
German Cancer Research Center
Phase 2 Recruiting
NCT05498896 2025-03-10
BARBICAN
Queen Mary University of London
Phase 2 Active not recruiting
NCT04551521 2025-01-08
CRAFT: The NCT-PMO-1602 Phase II Trial
German Cancer Research Center
Phase 2 Completed
NCT04464174 2024-07-26
PATHFINDER
MedSIR
Phase 2 Completed
NCT03395899 2024-06-18
ECLIPSE
Queen Mary University of London
Phase 2 Completed
NCT03853707 2024-02-20
Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer
City of Hope Medical Center
Phase 1/2 Completed
NCT04737109 2023-11-13
ADDItion
Big Ten Cancer Research Consortium
Phase 1/2 Terminated
NCT04467801 2023-11-07
Ipat-Lung
University of Kansas Medical Center
Phase 2 Unknown
NCT04920708 2023-10-27
FAIM
Royal Marsden NHS Foundation Trust
Phase 2 Recruiting
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT04739202 2021-03-29
IMMUNOGAST
Hospices Civils de Lyon
Phase 2 Unknown
NCT04561817 2020-10-06
To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Withdrawn